Determination of Orelabrutinib in Human Plasma Using LC-MS/MS.
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic drug monitoring"
DOI: 10.1097/ftd.0000000000001106
Abstract: BACKGROUND Orelabrutinib is a second-generation Bruton tyrosine kinase inhibitor that improves the management of B-cell malignancies. The objective of this study was to develop and validate an LC-MS/MS method for quantifying orelabrutinib in human plasma.… read more here.
Keywords: human plasma; plasma using; determination orelabrutinib; plasma ... See more keywords